A Cost-Effectiveness Analysis of Gefitinib as the First Line Treatment in Patients With Positive Egfr Mutation In Metastatic or Locally Advanced non-Small Cell
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1110
https://www.valueinhealthjournal.com/article/S1098-3015(15)03186-1/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
613
First Page :
A446
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03186-1&doi=10.1016/j.jval.2015.09.1110